CHEK1 and acute lymphoblastic leukemia: Following treatment with the ATR inhibitor VE-821 or the CHK1 inhibitor prexasertib on doxorubicin-exposed cells, their study revealed that inhibiting the ATR-CHK1 pathway enhances the cytotoxic effects of doxorubicin in ALL cells [36].